相关实验视频
Updated: Jun 1, 2025

Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
在接受门诊上部内镜检查的患者中,与使用葡萄糖样-1受体激动剂相关的内镜和麻醉结果
Sarjukumar Panchal1, Nadim Mahmud2, Joshua H Atkins3
1Division of Gastroenterology and Hepatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
类似葡萄糖-1受体激动剂 (GLP-1RAs) 在上部内镜和手术取消期间增加保留的胃含量. 然而,GLP-1RA的使用并没有增加麻醉风险,在两组中观察到类似的不良事件.
科学领域:
- 胃肠病学 胃肠病学
- 麻醉学 麻醉学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类似葡萄糖类-1受体激动剂 (GLP-1RAs) 与延迟胃排空有关.
- 这种效应引起了人们在内镜手术期间保留的胃内容 (RGC) 和潜在的麻醉并发症的担忧.
- 了解这些风险对于门诊患者的安全至关重要.
研究的目的:
- 调查GLP-1RA使用与内镜检查期间的结果之间的关联.
- 为了确定GLP-1RA对留存的胃含量 (RGC) 的影响.
- 评估GLP-1RA与麻醉不良事件之间的关系.
主要方法:
- 追溯队列研究涉及598名接受门诊内镜检查的患者.
- 患者被分为GLP-1RA组 (≥6周暴露) 和对照组.
- 评估的结果包括固体RGC,手术流产和不良麻醉事件.
主要成果:
- GLP-1RA组在上部内镜检查期间显示出固体RGC的几率明显更高 (OR,3.80;P = .003).
- 在GLP-1RA组中更频繁地中止手术 (1.3%对0%;P = .021).
- 同时进行结肠镜检查时没有观察到RGC的风险增加;缺氧率在各组之间是相似的.
结论:
- 使用GLP-1RA与在上部内镜检查期间增加固体RGC和更高的手术流产率有关.
- 同时进行结肠镜检查减轻了GLP-1RAs患者的RGC风险.
- GLP-1RA治疗似乎没有增加不良麻醉事件的风险.
更多相关视频
05:39Author Spotlight: A Non-Intubated Video-Assisted Thoracoscopic Surgery with Multimodal Analgesia and Sevoflurane Inhalation Anesthesia
Published on: May 26, 2023
05:43Topical Airway Anesthesia for Awake-endoscopic Intubation Using the Spray-as-you-go Technique with High Oxygen Flow
Published on: January 13, 2017
相关概念视频
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Endoscopic Procedures I: Esophagogastroduodenoscopy
During an EGD, the endoscope can be used to:
Hypoglycemia and Glucagon
Endoscopic Procedures V: ERCP
Patient...
Oral Hypoglycemic Agents: Glinides